肝癌患者行经导管肝动脉化疗栓塞术的奥沙利铂剂量研究 点击下载
论文标题: 肝癌患者行经导管肝动脉化疗栓塞术的奥沙利铂剂量研究
英文标题:
中文摘要: 目的:探讨不同剂量奥沙利铂对行经导管肝动脉化疗栓塞术(TACE)肝癌(HCC)患者相关指标的影响。方法: 100例HCC患者按随机数字表法分为对照组(50例)和观察组(50例)。TACE后,对照组患者动脉灌注注射用奥沙利铂40 mg/m2,每日1次+注射用盐酸表柔比星20 mg,每日1次,同时给予少许碘油;观察组患者动脉灌注注射用奥沙利铂80 mg/m2(用法同对照组)+注射用盐酸表柔比星(用法用量同对照组),同时给予少许碘油;观察两组患者术后3 d的丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、白细胞计数(WBC)、甲胎蛋白(AFP)水平,随访两组患者1年、3年总生存率(OS)及不良反应发生情况。结果:观察组患者腹痛、恶心呕吐发生率、ALT、AST、TBIL水平均显著高于对照组, WBC显著低于对照组,差异均有统计学意义(P<0.05)。两组患者发热、脱发、外周神经毒性发生率、1年及3年OS、AFP比较,差异均无统计学意义(P>0.05)。结论:80 mg/m2奥沙利铂较40 mg/m2对HCC患者TACE后可减少腹痛、恶心呕吐的发生,但其他效果不如40 mg/m2奥沙利铂且并不能延长患者的生存时间。
英文摘要: OBJECTIVE: To investigate the effect of different doses of oxaliplatin on the efficacy and safety and related indexes of patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). METHODS: 100 HCC patients were randomly divided into control group (50 cases) and observation group (50 cases). After TACE, control group received arterial infusion chemotherapy of 40 mg/m2 oxaliplatin, once a day+20 mg Epirubicin hydrochloride for injection, once a day, with little lipiodol. Observation group received arterial infusion chemotherapy of 80 mg/m2 oxaliplatin (the same usage with control group)+Epirubicin hydrochloride for injection (the same dosage with control group), with little lipiodol. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), white blood cell count (WBC) and alpha-fetoprotein (AFP) in 2 groups after 3 d treatment were observed, and the total overall survival (OS) and the incidence of adverse reactions were followed-up. RESULTS: Abdominal pain, incidences of nausea and vomiting, ALT, AST and TBIL in observation group were significantly higher than control group, WBC was significantly lower than control group, the differences were statistically significant (P<0.05). There were no significant differences in fever, hair loss, incidence of peripheral neurotoxicity, OS in 1 year and 3 years, and AFP in 2 groups (P>0.05). CONCLUSIONS: Compared with 40 mg/m2 oxaliplatin, 80 mg/m2 can reduce the incidence of abdominal pain, nausea, vomiting, but other effects are poor than 40 mg/m2, and it can not prolong the survival time of patients.
期刊: 2016年第27卷第18期
作者: 李刚,于翔,谢坪,蒲红
英文作者: LI Gang,YU Xiang,XIE Ping,PU Hong
关键字: 奥沙利铂;经导管肝动脉化疗栓塞;肝癌;不同剂量
KEYWORDS: Oxaliplatin; Transcatheter arterial chemoembolization; Hepatocellular carcinoma; Different dose
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!